Tyra Biosciences, Inc. (TYRA)
NASDAQ: TYRA · Real-Time Price · USD
10.94
+0.46 (4.39%)
May 2, 2025, 4:00 PM EDT - Market closed
Tyra Biosciences Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Tyra Biosciences stock have an average target of 30.5, with a low estimate of 28 and a high estimate of 33. The average target predicts an increase of 178.79% from the current stock price of 10.94.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 31, 2025.
Analyst Ratings
The average analyst rating for Tyra Biosciences stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 3 | 3 | 3 | 3 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 6 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $30 | Strong Buy | Reiterates | $30 | +174.22% | Mar 31, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $30 | Strong Buy | Reiterates | $30 | +174.22% | Feb 18, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $30 | Strong Buy | Reiterates | $30 | +174.22% | Jan 13, 2025 |
| UBS | UBS | Strong Buy Initiates $28 | Strong Buy | Initiates | $28 | +155.94% | Jan 7, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $32 → $30 | Strong Buy | Maintains | $32 → $30 | +174.22% | Nov 11, 2024 |
Financial Forecast
Revenue This Year
n/a
from 290.68M
Revenue Next Year
n/a
EPS This Year
-2.21
from -1.51
EPS Next Year
-2.41
from -2.21
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | n/a | 20.5M | ||
| Avg | n/a | n/a | 10.7M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.95 | -1.76 | -2.51 | ||
| Avg | -2.21 | -2.41 | -2.66 | ||
| Low | -2.35 | -2.94 | -2.74 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.